User menu

Feasibility of (90)Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Bibliographic reference Lhommel, Renaud ; Van Elmbt, Larry ; Goffette, Pierre ; Van den Eynde, Marc ; Jamar, François ; et. al. Feasibility of (90)Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, no. 9, p. 1654-1662 (2010)
Permanent URL
  1. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006;42(8):994–1003.
  2. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13S–7.
  3. Flux Glenn, Bardies Manuel, Monsieurs Myriam, Savolainen Sauli, Strand Sven-Erik, Lassmann Michael, The Impact of PET and SPECT on Dosimetry for Targeted Radionuclide Therapy, 10.1078/0939-3889-00291
  4. Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34(10):1699–700.
  5. Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34(5):772–86.
  6. Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med 2008;38(5):321–34.
  7. Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med 2008;38(5):308–20.
  8. Mansberg R, Sorensen N, Mansberg V, Van der Wall H. Yttrium 90 Bremsstrahlung SPECT/CT scan demonstrating areas of tracer/tumour uptake. Eur J Nucl Med Mol Imaging 2007;34(11):1887.
  9. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys 1994;21(9):1409–17.
  10. Minarik D, Sjögreen Gleisner K, Ljungberg M. Evaluation of quantitative (90)Y SPECT based on experimental phantom studies. Phys Med Biol 2008;53(20):5689–703.
  11. Sgouros G. Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis. Med Phys 1998;25(8):1487–90.
  12. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46(1):92S–8.
  13. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(1):99S–106.
  14. Walrand Stéphan, Jamar François, Mathieu Isabelle, Camps Joëlle, Lonneux Max, Sibomana Mérence, Labar Daniel, Michel Christian, Pauwels Stanislas, Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86, 10.1007/s00259-002-1068-y
  15. Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for removal of spurious activity introduced by cascade gamma rays. Med Phys 2003;30(9):2410–23.
  16. Buchholz H. G., Herzog H., Förster G. J., Reber H., Nickel O., Rösch F., Bartenstein P., PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction, 10.1007/s00259-002-1112-y
  17. Kull Thomas, Ruckgaber Jochen, Weller Rolf, Reske Sven, Glatting Gerhard, Quantitative Imaging Of Yttrium-86 Pet with the Ecat Exact Hr+In 2D Mode, 10.1089/cbr.2004.19.482
  18. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.
  19. de Jong M, Bakker WH, Krenning EP, Breeman WAP, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368–71.
  20. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47(9):1467–75.
  21. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med 2008;49:1884–99.
  22. Quadri SM, Shao Y, Blum JE, Leichner PK, Williams JR, Vriesendorp HM. Preclinical evaluation of intravenously administered 111In- labeled and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs. Nucl Med Biol 1993;20(5):559–70.
  23. Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med 1999;40(2):268–76.
  24. Ford K. Predicted 0+ level of Zr90. Phys Rev 1955;98:1516.
  25. Nickles RJ, Roberts AD, Nye JA, Converse AK, Barnhart TE, Avila-Rodriguez MA, et al. Assaying and PET imaging of yttrium-90: 1>>34 ppm>0. IEEE Nucl Sci Symp Conf Rec 2004;6:3412–4.
  26. Selwyn RG, Nickles RJ, Thomadsen BR, DeWerd LA, Micka JA. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot 2007;65:318–27.
  27. Langhoff H, Hennies H. Zum experimentellen Nachweis von Zweiquantenzerfall beim 0+-0+-Übergang des Zr90. Z Phys 1961;164:166–73.
  28. Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI, et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 2009;36:1696. doi: 10.1007/s00259-009-1210-1 .
  29. Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med 2007;48(12):2080–6.
  30. Campbell Janice M., Wong C. Oliver, Muzik Otto, Marples Brian, Joiner Michael, Burmeister Jay, Early Dose Response to Yttrium-90 Microsphere Treatment of Metastatic Liver Cancer by a Patient-Specific Method Using Single Photon Emission Computed Tomography and Positron Emission Tomography, 10.1016/j.ijrobp.2008.12.058
  31. Bilbao JI, Reiser MF, editors. Liver radioembolization with 90Y microspheres (medical radiology/diagnostic imaging). Berlin: Springer; 2008. p. 86.
  32. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471–80.
  33. Wang W, Hu Z, Gualtieri EE, Parma MJ, Walsh ES, Sebok D, et al. Systematic and distributed time-of-flight list mode PET reconstruction. IEEE Nucl Sci Symp Conf Rec 2006;3:1715–22.
  34. Daube-Witherspoon ME, Matej S, Karp JS, Lewitt RM. Application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging. IEEE Trans Nucl Sci 2001;48(1):24–30.
  35. Cross WG, Freedman NO, Wong PY. Tables of beta-ray dose distributions in water. Ontario: Atomic Energy of Canada, Ltd, Report No AECL-10521; 1992. .
  36. Franquiz JM, Chigurupati S, Kandagatla K. Beta voxel S values for internal emitter dosimetry. Med Phys 2003;30(6):1030–2.
  37. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, et al. MIRD Pamphlet No. 17: the dosimetry of nonuniform activity distributions—radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 1999;40:11S–36.
  38. Vardi Y, Lee D. From image deblurring to optimal investments: maximum likelihood solutions for positive linear inverse problems. J R Stat Soc Series B Stat Methodol 1993;55(3):569–612.
  39. Phelps ME, editor. PET: physics, instrumentation, and scanners. New York: Springer; 2006.
  40. .
  41. Kennedy Andrew, Nag Subir, Salem Riad, Murthy Ravi, McEwan Alexander J., Nutting Charles, Benson Al, Espat Joseph, Bilbao Jose Ignacio, Sharma Ricky A., Thomas James P., Coldwell Douglas, Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium, 10.1016/j.ijrobp.2006.11.060
  42. US Nuclear Regulatory Commission. 2007–10: yttrium-90 theraspheres and sirspheres impurities. Washington, DC: US Nuclear Regulatory Commission; 2007. NRC Information Notice.
  43. Stabin M, Konijnenberg M. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000;41(1):149–60.
  44. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.
  45. Moszynski M. NATO security through science series: radiation detectors for medical applications. Dordrecht: Springer; 2006. p. 293–315.
  46. Pepin CM, Berard P, Perrot AL, Pepin C, Houde D, Lecomte R, et al. Properties of LYSO and recent LSO scintillators for phoswich PET detectors. IEEE Trans Nucl Sci 2004;51(3):789–95.
  47. Pidol L, Kahn-Harari A, Viana B, Virey E, Ferrand B, Dorenbos P, et al. High efficiency of lutetium silicate scintillators, Ce-doped LPS, and LYSO crystals. IEEE Trans Nucl Sci 2004;51(3):1084–7.